A Case of Peritoneal Tuberculosis Developed after Infliximab Therapy for Refractory RA |
Min, Ji-Yeon
(Department of Internal Medicine, Hanyang University Guri Hospital, Hanyang University College of Medicine)
Bang, So-Young (Department of Internal Medicine, Hanyang University Guri Hospital, Hanyang University College of Medicine) Min, Seung-Yeon (Department of Internal Medicine, Hanyang University Guri Hospital, Hanyang University College of Medicine) Lee, Dae-Sung (Department of Internal Medicine, Hanyang University Guri Hospital, Hanyang University College of Medicine) Kim, Bo-Sang (Department of Internal Medicine, Hanyang University Guri Hospital, Hanyang University College of Medicine) Kim, Jeong-Eun (Department of Internal Medicine, Hanyang University Guri Hospital, Hanyang University College of Medicine) Lee, Eun-Sung (Department of Internal Medicine, Hanyang University Guri Hospital, Hanyang University College of Medicine) Pyo, Ju-Yeon (Department of Pathology, Hanyang University Guri Hospital, Hanyang University College of Medicine) Sohn, Jang-Won (Department of Internal Medicine, Hanyang University Guri Hospital, Hanyang University College of Medicine) Kim, Tae-Hyung (Department of Internal Medicine, Hanyang University Guri Hospital, Hanyang University College of Medicine) Lee, Hye-Soon (Department of Internal Medicine, Hanyang University Guri Hospital, Hanyang University College of Medicine) |
1 | Park H, Park CW, Kim KB, Lee MJ, Zeon SJ, Shim SC, et al. A case of peritoneal tuberculosis with Poncet's disease in a patient treated with infliximab. J Rheum Dis 2011;18:55-9. DOI |
2 | Kim IT, Park HB, Lee SH, Hyun YK, Kim YJ, Lee YW, et al. Tuberculous peritonitis in a patient with rheumatoid arthritis treated with infliximab. J Rheum Dis 2011;18:320-3. DOI |
3 | Park JH, Seo GY, Lee JS, Kim TH, Yoo DH. Positive conversion of tuberculin skin test and performance of interferon release assay to detect hidden tuberculosis infection during anti-tumor necrosis factor agent trial. J Rheumatol 2009;36:2158-63. DOI |
4 | Kievit W, Fransen J, Adang EM, den Broeder AA, Bernelot Moens HJ, Visser H, et al. Long-term effectiveness and safety of TNF-blocking agents in daily clinical practice: results from the Dutch Rheumatoid Arthritis Monitoring register. Rheumatology (Oxford) 2011;50:196-203. DOI |
5 | Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Ustianowski A, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010;69:522-8. DOI |
6 | Wolfe F, Michaud K, Anderson J, Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 2004;50:372-9. DOI |
7 | Seong SS, Choi CB, Woo JH, Bae KW, Joung CL, Uhm WS, et al. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers. J Rheumatol 2007;34:706-11. |
8 | Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha- neutralizing agent. N Engl J Med 2001;345:1098-104. DOI |
9 | Kwok SK, Park SH. Guidelines for prevention of tuberculosis in patients with rheumatoid arthritis treated with TNF-alpha blockers. J Korean Rheum Assoc 2007;14:105-11. DOI |
10 | Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD; BIOBADASER Group. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003;48:2122-7. DOI |
11 | Kang YA, Lee HW, Yoon HI, Cho B, Han SK, Shim YS, et al. Discrepancy between the tuberculin skin test and the whole-blood interferon gamma assay for the diagnosis of latent tuberculosis infection in an intermediate tuberculosis-burden country. JAMA 2005;293:2756-61. DOI |
12 | Furst DE, Wallis R, Broder M, Beenhouwer DO. Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Semin Arthritis Rheum 2006;36:159-67. DOI |
13 | Ponce de Leon D, Acevedo-Vasquez E, Sanchez-Torres A, Cucho M, Alfaro J, Perich R, et al. Attenuated response to purified protein derivative in patients with rheumatoid arthritis: study in a population with a high prevalence of tuberculosis. Ann Rheum Dis 2005;64:1360-1. DOI |
14 | Ponce de Leon D, Acevedo-Vasquez E, Alvizuri S, Gutierrez C, Cucho M, Alfaro J, et al. Comparison of an interferon-gamma assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population. J Rheumatol 2008;35:776-81. |